drugset / Trial / NCT02416999
Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas
NaSingle-groupOpen-labelTreatment
Summary
This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.
Timeline
- Start
- 2015-05
- Primary completion
- 2018-05
- Completion
- 2018-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Temozolomide | Small molecule | — | — |